ArticleFrontiers in endocrinology2026
Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, have demonstrated substantial efficacy in weight management. However, real-world treatment experience, tolerability, and treatment continuation remain important challenges, and the determinants of patient satisfaction are not fully understood. Methods: A cross-sectional online survey was conducted between January and February 2025 across international incretin therapy communities. The study included 411 adults with obesity (BMI ≥30 kg/m²) or overweight with comorbidities (BMI 27-29.9 kg/m²) receiving semaglutide or tirzepatide for ≥3 months. Treatment satisfaction was assessed using the validated Treatment-Related Impact Measure-Weight (TRIM-Weight). Patient-reported changes in appetite regulation, mood, physical activity, sexual health, self-image, and social experiences were evaluated using 5-point Likert scales. Results: Participants had a median age of 39 years (IQR 33-47), 71.8% were female, and the median treatment duration was 10 months (IQR 7-13), with 34.3% reporting treatment for ≥12 months. In univariate analyses, higher treatment satisfaction was associated with improvements in appetite regulation, mood, physical activity, sexual satisfaction, self-image, and positive social feedback, as well as fewer limitations due to side effects (all p < 0.05). In fully adjusted multivariable models, fewer limitations due to side effects (β = 1.41; 95% CI 0.25-2.88), increased satiety (β = 0.68; 95% CI 0.10-1.29), improved mood (β = 0.69; 95% CI 0.19-1.28), and higher physical activity (β = 0.58; 95% CI 0.10-1.17) remained independently associated with higher TRIM-Weight scores. Greater BMI reduction was associated with higher treatment satisfaction in the individually adjusted model, but this association was attenuated and no longer statistically significant in the fully adjusted model. Conclusions: Treatment satisfaction was more strongly associated with tolerability, satiety, mood, and physical activity than with BMI change or medication type. These findings support incorporating patient-reported outcomes when evaluating incretin-based therapies in real-world obesity care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.